Influence of glycopyrronium bromide formoterol fumarate inhalation aerosol on serum TIMP-1,LTB4 and arterial blood gas indexes in patients with stable chronic obstructive pulmonary disease
Objective To investigate the influence of glycopyrronium bromide formoterol fumarate inhalation aerosol on serum levels of tissue inhibitor of metalloproteinase-1(TIMP-1),leukotriene B4(LTB4)and arterial blood gas indexes in patients with stable chronic obstructive pulmonary disease(COPD).Methods According to the simple randomization grouping method,the patients with stable COPD admitted to our hospital from March 2021 to September 2023 were divided into the observation group and control group,with 45 patients in each group.The patients in the observation group were treated with glycopyrronium bromide formoterol fumarate inhalation aerosol,and those in the control group with budesonide formoterol inhaled powder inhalation(Ⅱ).All the patients in both groups were continuously treated for 3 months.The clinical efficacy,occurrence of adverse reactions and acute attack frequency during treatment and levels of pulmonary function indexes,serum TIMP-1,LTB4 and arterial blood gas indexes before treatment and after 3 months of treatment were compared between the 2 groups.Results After 3 months of treatment,the clinical efficacy in the observation group was higher than that in the control(93.33%vs 77.78%,P<0.05).The adverse reaction rate revealed no statistical difference between the two groups(P>0.05),and the acute attack frequency in the observation group was(0.98±0.12)times,which was lower than that of(1.11±0.19)times in the control(P<0.05).The forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)and arterial partial pressure of oxygen(PaO2)in the two groups were enhanced after 3 months of treatment than those before treatment.The above indexes in the observation group were higher than those in the control((2.88±0.41) L vs(2.62±0.43) L,(3.21±0.33) L vs(2.94±0.40) L,(60.13±5.23) L·min-1 vs(57.27±5.27) L·min-1,(77.17±2.34) mm Hg(1 mm Hg≈0.133 kPa)vs(75.51±2.20) mm Hg,P<0.05).Serum TIMP-1,LTB4 and arterial partial pressure of carbon dioxide(PaCO2)were reduced in both groups than those before treatment,and the observation group had lower indicators((58.32±4.10)μg·L-1 vs(60.97±4.36) μg·L-1,(106.56±6.79) ng·L-1 vs(110.23±7.57) ng·L-1,(46.58±2.42) mm Hg vs(48.43±2.46) mm Hg,P<0.05).Conclusion Glycopyrronium bromide formoterol fumarate inhalation aerosol has good efficacy and safety in the treatment of patients with stable COPD,and can significantly improve the levels of pulmonary function indexes,serum TIMP-1,LTB4 and arterial blood gas indexes.
Glycopyrronium bromide formoterol fumarate inhalation aerosolStable stageTissue inhibitor of metalloproteinase-1Leukotriene B4Arterial blood gas index
NETL
NSTL
万方数据
